Index

• Enzene Biosciences raises $50 million, aims to expand into global markets
• Paradigm Launches with $203 Million to Rebuild the Clinical Research Ecosystem
• Structure Therapeutics Appoints Industry Leaders Eric Dobmeier and Joanne Waldstreicher to its Board of Directors
• Whatfix ISV Partnership Program Grows Rapidly, Empowering Software Providers to Deliver Better User Experience and Accelerate Customer Adoption
• Jefferson County to Use Eleos Health’s Augmented Intelligence to Give Therapists More Time to Serve Those With Mental Illness
• Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target
• Community Services Group Taps Eleos Health for Augmented Intelligence Support in Behavioral Healthcare
• Insilico Medicine launches 6th generation Intelligent Robotics Lab to further accelerate its AI-driven drug discovery
• X-Chem and Sironax Begin Neurodegenerative Disease Drug Discovery Research Partnership
• Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
• Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
• Innovent Announces NMPA’s Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer
• Patina announces partnerships with major national Medicare Advantage plans, significantly expanding the reach of its unique primary care experience for adults 65+ in Philadelphia region
• Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT
• Comanche Biopharma Announces Appointment of Allison August, M.D., as Chief Medical Officer
• Alternative Bio Launches with USD 15M Series Seed Financing Led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund
• Immuneel Therapeutics Presents Early Data from India for Varnimcabtagene Autoleucel at ASH Annual Meeting
• ABK Biomedical Raises USD 30M in Series C Financing
• Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole
• Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
• Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
• Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
• Rallybio, AbCellera form new partnership around antibodies for rare disease
• Protenus CTO Michael Baglio Wins Top Healthcare Tech CTO Award
• NOCD Educates Record Number of People During 2022 OCD Awareness Month
• AllHealth Network Selects Eleos Health to Deliver In-Session Automation, Reducing Clinician Burden and Improving Care
• Adela’s Co-Founder & Chief Scientific Officer to Deliver Plenary Session at American Association for Cancer Research (AACR) Special Conference on Precision Prevention, Early Detection, and Interception of Cancer
• SonderMind picks up neuroscience company Total Brain to build out data-driven mental healthcare
• Centivo’s Virtual Primary Care practice receives NCQA Patient-Centered Medical Home Recognition
• Capital Rx is Crowned Winner of the Fierce Healthcare Fierce Innovation Award
• Deal Engine Raises $5.3M to Simplify Post-Booking Travel Transactions
• RareCyte® selected for the Wellcome Leap In Utero program; will utilize its rare cell liquid biopsy platform to perform breakthrough research to decrease stillbirth rates worldwide
• RareCyte® selected for the Wellcome Leap In Utero program; will utilize its rare cell liquid biopsy platform to perform breakthrough research to decrease stillbirth rates worldwide
• Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN
• Turnstone Biologics Announces FDA Clearance of IND for TIDAL-01, a Next-Generation TIL Therapy for Solid Tumors
• Cytek® Biosciences Names Chris Williams Chief Operating Officer
• Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors
• ConnexPay Secures $110 Million Growth Investment Led by FTV Capital to Propel Global Expansion and Unify Payments Ecosystem
• Prime Medicine Announces Closing of Upsized Initial Public Offering
• Devoted Health Achieves Top 5 out of 5 Medicare Advantage Star Rating for Ohio HMO Plans in First Year of Eligibility
• BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments
• Bayer, Hua Medicine snag first-in-class nod in China for Roche castoff diabetes drug, but commercial value uncertain
• AppliedVR Wins Q3 2022 Comparably Awards-recognized for Happiest Employees, Best Company Compensation, Best Work-Life Balance and Best Perks & Benefits
• The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma
• OSF HealthCare Partnering with US HealthVest on new behavioral health hospital
• New Mental Health Company Led by Consumer Brand Industry Veterans to Revolutionize Mental Health Care Delivery for Seniors
• Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
• Elucidata Raises $16 Million Series A to Reimagine AI Infrastructure for the Life Sciences Industry
• Prime Medicine spells out IPO plans for ‘word processor’ of gene editing
• NodThera Announces Positive Phase 1 Study Readouts for the NLRP3 Inflammasome Inhibitors NT-0796 and NT-0249
• Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B Infection
• RIGImmune Announces Acquisition of Antiviral Company Subintro and Concurrent Financing by F-Prime Capital
• Provider search firm Kyruus buys patient engagement company Epion Health
• AviadoBio selected by Fierce Biotech as a ‘Fierce 15’ 2022 winner
• Artemis Health and Zerigo Health Announce Partnership to Help Employers and Health Plans Better Evaluate and Manage Chronic Autoimmune Skin Conditions
• Benchling Launches the First Complete Solution for RNA R&D to Accelerate mRNA and RNA Therapeutics Development
• Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study
• Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes Name from ShouTi
• Centivo names Jim Foreman Chairman of the Board of Directors
• Latchel Closes $16.7 Million to Enhance Resident Services and Maintenance Workflow
• Vitalxchange Joins Buoy Health’s Marketplace to Provide Special Needs and Disability Parenting Solutions
• AppliedVR Announces Results from a Clinical Trial Follow-up Study Finding RelieVRx Delivers Durable Effects Six Months After Completing Treatment
• Morgan Health Announces New Investment in Centivo
• Eleos Expands Leadership Team with R&D, Finance Hires
• Protenus Recognized as a Top Healthcare Compliance Provider
• WelbeHealth Becomes First Program of All-Inclusive Care for the Elderly (PACE) Provider to Convert to Public Benefit Company Status
• Kyruus Announces Paul Merrild as Company’s First President
• Protenus is Top-Performing Solution in KLAS Drug Diversion Monitoring 2022 Report
• Snapdocs and STRATMOR Group Collaborate to Advance Borrower Experience Research
• Equip Publishes Study Showing Virtual Treatment is Highly Effective for Eating Disorders as Company Expands to 50 States
• Sondermind -The Company Redesigning Behavioral Health For Patients And Therapists
• Immuneel Therapeutics raises $15 million in funding
• Insilico Medicine appoints Dr. Feng Ren as co-CEO
• Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
• Vendr Raises $150MM Series B to Help CFOs Reduce Software Expense
• As their first clinical data test looms, global AI player Insilico bumps up a GSK vet to co-CEO in charge of development
• Has Denali found a way to correct gene mutations linked to Parkinson’s? Possibly, but questions remain
• PROXIMIE RAISES $80 MILLION IN SERIES C FUNDING TO ACCELERATE PRODUCT EXPANSION OF FULL-SERVICE CONNECTED SURGICAL PLATFORM
• Singular Genomics and Olink collaborate to enable Olink® Explore on the G4 Max Read™ sequencing kits
• Big names, big backers: David Baker joins OrbiMed, F-Prime, Khosla and others as protein-ligand biotech launches
• Exclusive: Medical AI startup Owkin just secured $80 million as it gears up to enhance drug trials with the pharmaceutical giant Bristol Myers Squibb
• Singular Genomics and Olink collaborate to enable Olink® Explore on the G4 Max Read™ sequencing kits
• Ontrak Health and Eleos Announce AI Integration Partnership to Support Care for Ontrak Members
• Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory
• MediKarma Selects 1upHealth as its Interoperability Partner to Help Patients Acquire Their Medical Records from Hospital EMRs
• Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
• Sana Biotechnology ditches California manufacturing plans in bid to save $100M
• Sana Biotechnology ditches California manufacturing plans in bid to save $100M
• 1upHealth Selected by NCQA As Partner in Digital Quality Solutions Pilot
• SpectrumAi, an LA startup centered on autism, raised $9M in seed funding